Deerfield Management’s TherapeuticsMD TXMD Stock Holding History

Deerfield Management’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-45,000	Closed	-$5.45M	–	98
2019 Q4	$5.45M	Buy	+45,000	New	+$6.47M	0.17%	63
2015 Q2	–	Sell	-44,466	Closed	-$13.5M	–	135
2015 Q1	$13.5M	Buy	+44,466	New	+$10.9M	0.44%	56
2014 Q3	–	Sell	-2,224	Closed	-$492K	–	143
2014 Q2	$492K	Sell	2,224 -5,297	-70%	-$1.18M	0.02%	116
2014 Q1	$2.37M	Buy	+7,521	New	+$2.39M	0.1%	110
2013 Q4	–	Sell	-25,000	Closed	-$3.66M	–	124
2013 Q3	$3.66M	Buy	+25,000	New	+$3.02M	0.17%	87

Other funds holding TXMD

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management's TXMD Position: Q1 2020 in Review

Deerfield Management sold out of TherapeuticsMD (TXMD) in Q1 2020, closing a stake of 45,000 shares — an estimated $5.45M sold.

Deerfield Management first reported a position in TXMD in Q3 2013 and held it in 5 quarters. The position peaked at $13.5M in Q1 2015. 143 funds tracked by Wall St. Rank hold TXMD as of Q1 2020.

Deerfield Management reported no remaining TherapeuticsMD position as of Q1 2020 after selling out during the quarter.
Deerfield Management sold 45,000 TherapeuticsMD shares in Q1 2020, an estimated $5.45M.
Deerfield Management first reported a position in TherapeuticsMD in Q3 2013 and held it in 5 quarters.
Deerfield Management's TherapeuticsMD position peaked at $13.5M in Q1 2015.
143 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2020.

Based on Deerfield Management's 13F filing for Q1 2020, filed 15 May 2020.